Please login to the form below

Not currently logged in
Email:
Password:

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bluebird sign $100m cell therapies deal

Regeneron and Bluebird sign $100m cell therapies deal

Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its

Latest news

  • Immuno-oncology at ASCO: survival data, combinations and new indications Immuno-oncology at ASCO: survival data, combinations and new indications

    Finally, PD-1 latecomers Sanofi and Regeneron will share the first results from an early-stage trial of their candidate cemiplimab in NSCLC at ASCO, as a monotherapy in patients who

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    Schleifer spent a sizeable portion of the conference call talking up Regeneron’s emerging position in immuno-oncology, currently led by Sanofi-partnered PD-1 inhibitor cemiplimab, which is due for ... The company has chosen a first indication for

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    Regeneron-partnered cemiplimab is the first of the new wave of checkpoint inhibitors to be filed for CSCC, and also picked up a breakthrough designation from the FDA last September. ... Sanofi has three trials of cemiplimab either ongoing or planned in

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... Cemiplimab is one of nine drugs expected to be filed by Sanofi before the middle of next year, according to the

  • Sanofi and Regeneron ramp up immuno-oncology collaboration Sanofi and Regeneron ramp up immuno-oncology collaboration

    Sanofi and Regeneron ramp up immuno-oncology collaboration. Will put an additional $1bn in investigational candidate cemiplimab. ... Sanofi and Regeneron are set to give the development programme for their immuno-oncology candidate cemiplimab a $1bn boost

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics